Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
IGFBP4 Double Nickase Plasmid (h): sc-402342-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IGFBP4 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- IGFBP4 Double Nickase Plasmid (h) and IGFBP4 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting IGFBP4. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IGFBP4 Antibody (A3): sc-517440
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IGFBP4 Double Nickase Plasmid (h) | sc-402342-NIC | 20 µg | $410.00 | |||
IGFBP4 Double Nickase Plasmid (h2) | sc-402342-NIC-2 | 20 µg | $410.00 |
Insulin-like growth factor binding protein 4 (IGFBP4) is a secreted modulator of IGF-I and IGF-II bioavailability that regulates receptor engagement and downstream PI3K–AKT and MAPK signaling, shaping cellular proliferation, survival, and differentiation programs. By binding IGFs in the extracellular milieu, IGFBP4 can tune growth factor gradients and paracrine/autocrine responses within tissue remodeling contexts, including vascular and stromal microenvironments. Altered IGFBP4 expression or processing has been associated with dysregulated growth signaling observed in fibrosis, metabolic dysfunction, cardiovascular remodeling, and multiple cancer-related phenotypes. Consequently, IGFBP4 is frequently studied as a context-dependent regulator of IGF axis activity and extracellular signaling dynamics.
IGFBP4 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the IGFBP4 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within IGFBP4. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt IGFBP4 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of IGFBP4-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.